Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery

被引:38
作者
Gharse, Sachin [1 ]
Fiegel, Jennifer [2 ]
机构
[1] Univ Iowa, Dept Pharmaceut Sci & Expt Therapeut, Iowa City, IA 52245 USA
[2] Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52245 USA
基金
美国国家卫生研究院;
关键词
PulmoSpheres; nanoparticle aggregates; porosity; dispersibility; aerodynamic diameter; systemic circulation; MOLECULAR-WEIGHT HEPARIN; DIRECT LUNG DELIVERY; DRY POWDER; SUSTAINED-RELEASE; ALVEOLAR MACROPHAGES; PLGA MICROPARTICLES; IN-VITRO; FORMULATION; MICROSPHERES; PHAGOCYTOSIS;
D O I
10.2174/1381612822666160128145356
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The deep lungs provide an efficient pathway for drugs to transport into the systemic circulation, as the extremely large surface area and thin epithelial membrane enable rapid drug transport to the blood stream. To penetrate into the deep lungs, aerosol particles with aerodynamic diameters of 1-3 mu m are optimal. Large porous hollow particles (LPHPs) can achieve this aerodynamic size range through enhanced porosity within the particles (typically < 0.4 g/cm(3)), which aerodynamically balances the large particle size (>5 mu m, up to 30 mu m). The physical properties of these particles provide some key advantages compared to their small, nonporous counterparts through enhanced dispersibility, efficient deep lung deposition, and avoidance of phagocytic clearance. This review highlights the potential of LPHPs in pulmonary delivery of systemic drugs, with a focus on their critical attributes and key formulation aspects. In addition, three examples of LPHPs under development are presented to emphasize the potential of this technology to treat systemic diseases.
引用
收藏
页码:2463 / 2469
页数:7
相关论文
共 74 条
  • [1] Targeting to macrophages:: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages
    Ahsan, FL
    Rivas, IP
    Khan, MA
    Suárez, AIT
    [J]. JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) : 29 - 40
  • [2] Anderson Paula J, 2005, Respir Care, V50, P1139
  • [3] NanoCipro encapsulation in monodisperse large porous PLGA microparticles
    Arnold, Matthew M.
    Gonnan, Enic M.
    Schieber, Loren J.
    Munson, Eric J.
    Berkland, Cory
    [J]. JOURNAL OF CONTROLLED RELEASE, 2007, 121 (1-2) : 100 - 109
  • [4] Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs
    Ben-Jebria, A
    Chen, DH
    Eskew, ML
    Vanbever, R
    Langer, R
    Edwards, DA
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (04) : 555 - 561
  • [5] Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats
    Bosquillon, C
    Prat, W
    Vanbever, R
    [J]. JOURNAL OF CONTROLLED RELEASE, 2004, 96 (02) : 233 - 244
  • [6] Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance
    Bosquillon, C
    Lombry, C
    Préat, V
    Vanbever, R
    [J]. JOURNAL OF CONTROLLED RELEASE, 2001, 70 (03) : 329 - 339
  • [7] Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract
    Bot, AI
    Tarara, TE
    Smith, DJ
    Bot, SR
    Woods, CM
    Weers, JG
    [J]. PHARMACEUTICAL RESEARCH, 2000, 17 (03) : 275 - 283
  • [8] Rivaroxaban: A Review of Its Use in the Treatment of Deep Vein Thrombosis or Pulmonary Embolism and the Prevention of Recurrent Venous Thromboembolism
    Burness, Celeste B.
    Perry, Caroline M.
    [J]. DRUGS, 2014, 74 (02) : 243 - 262
  • [9] Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes
    Cai, Yunpeng
    Xu, Mingxin
    Yuan, Minglu
    Liu, Zhenguo
    Yuan, Weien
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2014, 9 : 3527 - 3538
  • [10] CANNON GJ, 1992, J CELL SCI, V101, P907